Key Points
- CorVel VP Jennifer Yoss sold 2,100 shares at an average price of $70.92, totaling $148,932. Following the sale, her direct ownership fell 49.15% to 2,173 shares.
- CorVel shares opened at $71.23, with a $3.63 billion market capitalization and a 52-week range of $44.83 to $93.45. The company recently reported quarterly EPS of $0.63 on revenue of $259.93 million.
- Analyst sentiment remains mixed but centered on a “Hold” consensus, while institutional investors and hedge funds own 51.36% of the stock; several funds recently initiated or expanded positions.
CorVel Corp. (NASDAQ:CRVL - Get Free Report) VP Jennifer Yoss sold 2,100 shares of CorVel stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $70.92, for a total value of $148,932.00. Following the sale, the vice president directly owned 2,173 shares of the company's stock, valued at approximately $154,109.16. This trade represents a 49.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Jennifer Yoss also recently made the following trade(s):
- On Tuesday, May 26th, Jennifer Yoss sold 1,999 shares of CorVel stock. The shares were sold at an average price of $61.02, for a total value of $121,978.98.
CorVel Trading Up 1.5%
NASDAQ:CRVL opened at $71.23 on Tuesday. CorVel Corp. has a 1-year low of $44.83 and a 1-year high of $93.45. The firm has a market capitalization of $3.63 billion, a price-to-earnings ratio of 31.66 and a beta of 0.98. The business's 50-day moving average price is $62.52 and its two-hundred day moving average price is $57.70.
CorVel (NASDAQ:CRVL - Get Free Report) last posted its earnings results on Tuesday, August 4th. The business services provider reported $0.63 earnings per share (EPS) for the quarter. The company had revenue of $259.93 million during the quarter. CorVel had a return on equity of 29.92% and a net margin of 11.72%.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on the stock. Wall Street Zen upgraded shares of CorVel from a "hold" rating to a "buy" rating in a report on Saturday, May 30th. Weiss Ratings upgraded shares of CorVel from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, July 16th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, CorVel has a consensus rating of "Hold".
Check Out Our Latest Report on CRVL
Hedge Funds Weigh In On CorVel
Several institutional investors and hedge funds have recently modified their holdings of CRVL. Walleye Capital LLC bought a new stake in shares of CorVel during the second quarter worth $3,308,000. NewEdge Wealth LLC bought a new stake in CorVel in the 2nd quarter valued at $1,956,000. M&T Bank Corp lifted its position in CorVel by 1,230.0% in the 4th quarter. M&T Bank Corp now owns 63,439 shares of the business services provider's stock valued at $4,293,000 after acquiring an additional 58,669 shares in the last quarter. OneDigital Investment Advisors LLC acquired a new position in CorVel in the 2nd quarter worth $1,101,000. Finally, Callan Family Office LLC acquired a new position in CorVel in the 2nd quarter worth $3,833,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.
CorVel Company Profile
(
Get Free Report)
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers' compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel's integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company's product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
